Pakistani scientists winning the race to complete research in immunoglobulin therapy to treat COVID-19
Scientists at Karachi’s Dow University of Health Sciences (DUHS) believe Pakistan is likely to become the first country to complete the research on intravenous immunoglobulin (C-IVIG) therapy for the treatment coronavirus. The scientist conducting the clinical trials needed to introduce the treatment at a mass level say that ‘severe’ patients who had received the product had a 100 percent recovery rate.
Health experts at the Dow University of Health Sciences, Karachi, discovered that certain variants of human genes resist against coronavirus. The study published in the Journal of Medical Virology states that 2 variants of ACE2 (Angiotensin-converting enzyme 2 gene) i.e. S19P and E329G might make an individual resistant to COVID-19. The experts analysed genome data of more than 1000 patients hailing from china and found that the patients had both the variants in extremely small quantities.